Background: The transmission of the coronavirus disease (COVID-19) pandemic resulted in new challenges across all medical specialities. A hypercoagulable state is being observed in many patients with SARS-CoV-2 and is a predictor of a worse prognosis. Acute limb ischemia (ALI) is a limb and life-threatening condition with high morbidity and mortality. It is a relatively rare manifestation of the spectrum of COVID-19 related coagulopathy. Methods: A single centre, prospective, interventional study was performed from JUNE 2020 to JUNE 2021 in post-COVID recovery patients who developed ALI using endovascular therapy for revascularisation. Data collected included demographics, anatomical location of the arterial occlusion, treatments, and outcomes. Results: Over the 13 months, a total of 38 patients participated in the study. The mean age is 64.45 years, ranging from 16-75 years. 25 (65.78%) are men. 30 (78.94%) participants had lower limb involvement, and 8 (21.06%) had upper limb involvement. Pain and pulselessness were present in all the patients. However, only four patients (10.52%) presented with paresis. Tibial arteries (most commonly) were affected in 24 (63.15%) patients. Radial arteries were involved in only 5.26%. 55.26% of presentations were Rutherford stage IIb. We used a combination of transluminal balloon angioplasty, thromboaspiration, Catheter-directed thrombolysis and stenting. Revascularisation was achieved in 35 (92.1%). Two (5.26%) patients were amputated. One (2.36%) patient died. Conclusion: A thorough understanding of endovascular techniques, associated pharmacology, and perioperative care is paramount to endovascular management success in patients presenting with AIL.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
